A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes

NCT07271251 · Active, not recruiting

Last updated 2026-05-28

This study is testing whether two different versions of an oral diabetes medication called semaglutide work equally well in lowering blood sugar levels in Japanese adults with type 2 diabetes.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 264 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-12 · est. completion 2026-08

Where 15 sites · Japan

What this study is testing ClinicalTrials.gov NCT07271251 ↗

Description as written by the study sponsor.

The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes. Participants will receive either oral semaglutide D (the treatment being tested) or oral semaglutide (the comparator); which treatment a participant gets is decided by chance. Oral semaglutide is an approved tablet (a treatment used as a comparator), while oral semaglutide D is described as the new tablet formulation being tested in this study. The study will last approximately 27 weeks.

Treatments tested

Oral semaglutide Drug

Semaglutide will be administered orally once daily.

Main thing measured	Change in glycated haemoglobin (HbA1c).
Sponsor	Novo Nordisk A/S
Conditions studied	Type 2 Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07271251 ↗